<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39377025</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.</ArticleTitle><Pagination><StartPage>e70119</StartPage><MedlinePgn>e70119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.70119</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) initiated the COVID-19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact. Despite the high efficacy of COVID-19 vaccines, they are also associated with several common side effects/complications, some of them specific to the multiple sclerosis population. Our goal is to review various types of COVID-19 vaccines, assessing their efficacy, adverse events, their association with an MS relapse following vaccination, and the influence of disease modifying therapies (DMTs) on vaccines' efficacy.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The review was based on a database search that included PubMed/Medline, Embase, Scopus, and the Web of Science conducted from January 2020 to July 2024 using the following MeSH terms: MS, COVID-19, COVID-19 vaccination, vaccine side effects, and vaccine hesitancy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Receiving any type of COVID-19 vaccine is a safer and more reliable approach to building immunity compared to becoming infected with the virus. Complications tend to be mild to moderate, occasionally severe. DMTs could affect the humoral response to the COVID-19 vaccine. Among all DMTs, a notable reduction in the humoral response has been observed in patients who received anti-CD20 and sphingosine-1-phosphate (S1P) receptor modulator drugs after their COVID-19 vaccination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Despite certain drawbacks, the benefits of the COVID-19 vaccine significantly outweigh the associated risks, making it a recommended course of action for people with multiple sclerosis (pwMS). However, physicians need to be mindful of potential complications especially in patients undergoing anti CD20 and manage them appropriately.</AbstractText><CopyrightInformation>© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmoudi</LastName><ForeName>Farhad</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9736-0760</Identifier><AffiliationInfo><Affiliation>Department of Neurology University of Miami Miami Florida USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirmosayyeb</LastName><ForeName>Omid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jacobs School of Medicine and Biomedical Sciences University at Buffalo, State University of New York Buffalo New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaabani</LastName><ForeName>Elnaz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Koch Institute for Integrative Cancer Research at MIT Massachusetts USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaffary</LastName><ForeName>Elham Moases</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Pharmacy School University of Missouri-Kansas City Kansas City Missouri USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology University of Miami Miami Florida USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">COVID‐19 vaccine</Keyword><Keyword MajorTopicYN="N">Multiple Sclerosis</Keyword><Keyword MajorTopicYN="N">disease‐modifying therapies</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39377025</ArticleId><ArticleId IdType="pmc">PMC11456691</ArticleId><ArticleId IdType="doi">10.1002/hsr2.70119</ArticleId><ArticleId IdType="pii">HSR270119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization
. WHO Coronavirus (COVID‐19) Dashboard 2023 [09/2023]. Available from: https://covid19.who.int
</Citation></Reference><Reference><Citation>Alam Z, Mohamed S, Nauman J, Al‐Rifai RH, Ahmed LA, Elbarazi I. Hesitancy toward vaccination against COVID‐19: a scoping review of prevalence and associated factors in the arab world. Hum Vaccines Immunother. 2023;19(2):2245720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10443971</ArticleId><ArticleId IdType="pubmed">37594508</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkotoky S, Dey D, Hazarika Z. Interactions of angiotensin‐converting enzyme‐2 (ACE2) and SARS‐CoV‐2 spike receptor‐binding domain (RBD): a structural perspective. Mol Biol Rep. 2023;50(3):2713‐2721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9786537</ArticleId><ArticleId IdType="pubmed">36562937</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira LMC, Coimbra JTS, Ramos MJ, Fernandes PA. Transmembrane protease serine 2 proteolytic cleavage of the SARS‐CoV‐2 spike protein: A mechanistic quantum Mechanics/Molecular mechanics study to inspire the design of new drugs to fight the COVID‐19 pandemic. J Chem Inf Model. 2022;62(10):2510‐2521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9113003</ArticleId><ArticleId IdType="pubmed">35549216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID‐19. Front Immunol. 2020;11:585354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591699</ArticleId><ArticleId IdType="pubmed">33163000</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169‐180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942519</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhani N, Tremlett H. The multiple sclerosis prodrome. Nat Rev Neurol. 2021;17(8):515‐521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324569</ArticleId><ArticleId IdType="pubmed">34155379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN. BNT162b2 mRNA COVID‐19 vaccine: first approval. Drugs. 2021;81(4):495‐501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938284</ArticleId><ArticleId IdType="pubmed">33683637</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Klaser K, May A, et al. Vaccine side‐effects and SARS‐CoV‐2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939‐949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078878</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA‐1273 vaccine against SARS‐CoV‐2 in nonhuman primates. N Engl J Med. 2020;383(16):1544‐1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review of SARS‐CoV‐2 vaccines: pfizer, moderna &amp; johnson &amp; johnson. Hum Vaccines Immunother. 2022;18(1):2002083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384(5):403‐416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Poland GA, Ovsyannikova IG, Kennedy RB. SARS‐CoV‐2 immunity: review and applications to phase 3 vaccine candidates. The Lancet. 2020;396(10262):1595‐1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553736</ArticleId><ArticleId IdType="pubmed">33065034</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshild V, Hirsh‐Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID‐19 vaccines: a systematic review and network meta‐analysis. Sci Rep. 2021;11(1):22777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaide M, Chocarro de Erauso L, Bocanegra A, Blanco E, Kochan G, Escors D. mRNA vaccines against SARS‐CoV‐2: advantages and caveats. Int J Mol Sci. 2023;24(6):5944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10051235</ArticleId><ArticleId IdType="pubmed">36983017</ArticleId></ArticleIdList></Reference><Reference><Citation>Joe CCD, Jiang J, Linke T, et al. Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs. Biotechnol Bioeng. 2022;119(1):48‐58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653296</ArticleId><ArticleId IdType="pubmed">34585736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID‐19 vaccines administered in the EU: should we be concerned? Toxicol Rep. 2021;8:871‐879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055532</ArticleId><ArticleId IdType="pubmed">33898273</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448‐2456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087975</ArticleId><ArticleId IdType="pubmed">33929487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to SARS‐CoV‐2 and COVID‐19. Cell. 2021;184(4):861‐880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty PK, Van Keulen VP, Erskine CL, et al. Antigen specific humoral and cellular immunity following SARS‐CoV‐2 vaccination in ANCA‐Associated vasculitis patients receiving B‐Cell depleting therapy. Front Immunol. 2022;13:834981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8831839</ArticleId><ArticleId IdType="pubmed">35154159</ArticleId></ArticleIdList></Reference><Reference><Citation>Clem A. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73‐78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068582</ArticleId><ArticleId IdType="pubmed">21572612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarjour NN, Masopust D, Jameson SC. T cell memory: understanding COVID‐19. Immunity. 2021;54(1):14‐18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749639</ArticleId><ArticleId IdType="pubmed">33406391</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehm M, Klippstein M, Dauth S, et al. Impact of different classes of immune‐modulating treatments on B cell‐related and T cell‐related immune response before and after COVID‐19 booster vaccination in patients with immune‐mediated diseases and primary immunodeficiency: a cohort study. RMD Open. 2023;9(3):e003094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10476126</ArticleId><ArticleId IdType="pubmed">37652553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. Am J Med. 2020;133(12):1380‐1390.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704606</ArticleId><ArticleId IdType="pubmed">32682869</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabreira V, Abreu P, Soares‐dos‐Reis R, Guimarães J, Sá MJ. Multiple sclerosis, disease‐modifying therapies and COVID‐19: a systematic review on immune response and vaccination recommendations. Vaccines. 2021;9(7):773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310076</ArticleId><ArticleId IdType="pubmed">34358189</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehl F. Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289(6):771‐791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8246813</ArticleId><ArticleId IdType="pubmed">33258193</ArticleId></ArticleIdList></Reference><Reference><Citation>
prevention Cfca
. People with Certain Medical Conditions: CDC; 2023.  [Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:~:text=Being%20immunocompromised%20can%20make%20you,to%20date%20on%20their%20vaccines
</Citation></Reference><Reference><Citation>Longinetti E, Bower H, McKay KA, et al. COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls. Ann Clin Transl Neurol. 2022;9(9):1449‐1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9463950</ArticleId><ArticleId IdType="pubmed">35993445</ArticleId></ArticleIdList></Reference><Reference><Citation>Marantos T, Kyriazopoulou E, Lekakis V, Voumvourakis KI, Tsiodras S. Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta‐analysis. J Neurol Sci. 2024;456:122852.</Citation><ArticleIdList><ArticleId IdType="pubmed">38142541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS‐CoV‐2 vaccines in rituximab‐treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177‐e187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700278</ArticleId><ArticleId IdType="pubmed">34977602</ArticleId></ArticleIdList></Reference><Reference><Citation>Marasco V, Carniti C, Guidetti A, et al. T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol. 2022;196(3):548‐558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653177</ArticleId><ArticleId IdType="pubmed">34649298</ArticleId></ArticleIdList></Reference><Reference><Citation>Madelon N, Lauper K, Breville G, et al. Robust T‐Cell responses in Anti‐CD20‐Treated patients following COVID‐19 vaccination: A prospective cohort study. Clin Infect Dis. 2022;75(1):e1037‐e1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767893</ArticleId><ArticleId IdType="pubmed">34791081</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikubo M, Shimomura Y, Yamamoto R, et al. Humoral and cellular responses after COVID‐19 booster vaccination in patients recently treated with anti‐CD20 antibodies. Blood Cancer J. 2023;13(1):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9868506</ArticleId><ArticleId IdType="pubmed">36690628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, De Rossi N, Schiavetti I, et al. Disease‐Modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780‐789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013440</ArticleId><ArticleId IdType="pubmed">33480077</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuth E, Nieminen V, Palomäki A, et al. Prolonged viral pneumonia and high mortality in COVID‐19 patients on anti‐CD20 monoclonal antibody therapy. Eur J Clin Microbiol Infect Dis. 2024;43(4):723‐734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10965662</ArticleId><ArticleId IdType="pubmed">38358552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J. Impact of disease‐modifying treatments on humoral response after COVID‐19 vaccination: a mirror of the response after SARS‐CoV‐2 infection. Rev Neurol. 2021;177(10):1237‐1240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206590</ArticleId><ArticleId IdType="pubmed">34172292</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose DR, Mahadeen AZ, Carlson AK, et al. Clinical features and outcomes of COVID‐19 despite SARS‐CoV‐2 vaccination in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7(4):205521732110571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673876</ArticleId><ArticleId IdType="pubmed">34925875</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakimovski D, Zakalik K, Awan S, et al. COVID‐19 vaccination in multiple sclerosis and inflammatory diseases: effects from disease‐modifying therapy, long‐term seroprevalence and breakthrough infections. Vaccines. 2022;10(5):695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146267</ArticleId><ArticleId IdType="pubmed">35632451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccone A, Mathey G, Prunis C, Debouverie M. Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod. Rev Neurol. 2023;179(3):223‐229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9727589</ArticleId><ArticleId IdType="pubmed">36496270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nytrova P, Stastna D, Tesar A, et al. Immunity following SARS‐CoV‐2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab. Front Immunol. 2023;14:1149629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10312310</ArticleId><ArticleId IdType="pubmed">37398654</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallantyre EC, Vickaryous N, Anderson V, et al. COVID‐19 vaccine response in people with multiple sclerosis. Ann Neurol. 2022;91(1):89‐100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652739</ArticleId><ArticleId IdType="pubmed">34687063</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle PK, Gocke A, Vignos M, Newsome SD. Vaccine considerations for multiple sclerosis in the COVID‐19 era. Adv Ther. 2021;38(7):3550‐3588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169434</ArticleId><ArticleId IdType="pubmed">34075554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gombolay GY, Dutt M, Tyor W. Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis. Ann Clin Transl Neurol. 2022;9(8):1321‐1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349877</ArticleId><ArticleId IdType="pubmed">35852423</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Fätkenheuer G, Hartung HP, et al. Vaccination in multiple sclerosis patients treated with highly effective disease‐modifying drugs: an overview with consideration of cladribine tablets. Ther Adv Neurol Disord. 2021;14:175628642110195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521756</ArticleId><ArticleId IdType="pubmed">34671422</ArticleId></ArticleIdList></Reference><Reference><Citation>Centonze D, Rocca MA, Gasperini C, et al. Disease‐modifying therapies and SARS‐CoV‐2 vaccination in multiple sclerosis: an expert consensus. J Neurol. 2021;268(11):3961‐3968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8038920</ArticleId><ArticleId IdType="pubmed">33844056</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiola L, Riva A, Nicoletti F, et al. Vaccination opportunities in multiple sclerosis patients treated with cladribine tablets. Curr Neuropharmacol. 2022;20(10):1811‐1815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886810</ArticleId><ArticleId IdType="pubmed">34923946</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, Berger T, Hartung HP, Oreja‐Guevara C, Bar‐Or A. Multiple sclerosis in the era of COVID‐19: disease course, DMTs and SARS‐CoV2 vaccinations. Curr Opin Neurol. 2022;35(3):319‐327.</Citation><ArticleIdList><ArticleId IdType="pubmed">35674075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernicová E, Macounová P, Krsek M, Maďar R. Summary of safety and efficacy of COVID vaccination in patients with multiple sclerosis. Eur Neurol. 2023;86(4):263‐276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10614228</ArticleId><ArticleId IdType="pubmed">36871554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamout BI, Zakaria M, Inshasi J, et al. MENACTRIMS practice guideline for COVID‐19 vaccination in patients with multiple sclerosis. Multiple Sclero Related Disord. 2021;56:103225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386106</ArticleId><ArticleId IdType="pubmed">34479111</ArticleId></ArticleIdList></Reference><Reference><Citation>von Oertzen TJ, Macerollo A, Leone MA, et al. EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic. Eur J Neurol. 2021;28(1):7‐14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675361</ArticleId><ArticleId IdType="pubmed">33058321</ArticleId></ArticleIdList></Reference><Reference><Citation>Day D, Grech L, Nguyen M, et al. Serious underlying medical conditions and COVID‐19 vaccine hesitancy: A large Cross‐Sectional analysis from Australia. Vaccines. 2022;10(6):851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230066</ArticleId><ArticleId IdType="pubmed">35746458</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanikić M, Twomey E, Puhan MA, et al. Experiences of persons with multiple sclerosis with the Covid‐19 vaccination: A cross‐sectional study of the Swiss multiple sclerosis registry. Multiple Sclerosis and Related Disorders. 2023;74:104707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080862</ArticleId><ArticleId IdType="pubmed">37068368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID‐19 vaccination in adults with multiple sclerosis in the United States. Multiple Sclerosis Related Disorders. 2021;49:102788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825851</ArticleId><ArticleId IdType="pubmed">33508570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdani A, Mirmosayyeb O, Ghaffary EM, Hashemi MS, Ghajarzadeh M. COVID‐19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta‐analysis. Neurol Sci. 2022;43(7):4085‐4094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983030</ArticleId><ArticleId IdType="pubmed">35381877</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. Neurological adverse reactions to SARS‐CoV‐2 vaccines. Clin Psychopharmacol Neurosci. 2023;21(2):222‐239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157009</ArticleId><ArticleId IdType="pubmed">37119215</ArticleId></ArticleIdList></Reference><Reference><Citation>Eren F, Aygul R, Tenekeci S, Ozturk S. Multifocal motor neuropathy after SARS‐CoV‐2 vaccination: a causal or coincidental association? J Int Med Res. 2022;50(7):030006052211107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9280831</ArticleId><ArticleId IdType="pubmed">35818160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series. Eur J Neurol. 2022;29(2):555‐563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652629</ArticleId><ArticleId IdType="pubmed">34668274</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari PJ, Chawda UB, Bhad BJ, Mevada AV, Jha SG. Facial palsy induced by covaxin in adolescent female ‐ A rare case report. Curr Drug Saf. 2023;18(4):603‐605.</Citation><ArticleIdList><ArticleId IdType="pubmed">36579394</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Tamborska AA, Doheim MF, et al. Neurological events reported after COVID‐19 vaccines: an analysis of vaccine adverse event reporting system. Ann Neurol. 2022;91(6):756‐771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082459</ArticleId><ArticleId IdType="pubmed">35233819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AY, Woo W, Yon DK, et al. Thrombosis patterns and clinical outcome of COVID‐19 vaccine‐induced immune thrombotic thrombocytopenia: A systematic review and Meta‐Analysis. Int J Infect Dis. 2022;119:130‐139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942584</ArticleId><ArticleId IdType="pubmed">35339716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID‐19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191‐2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9183215</ArticleId><ArticleId IdType="pubmed">35691322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalincik T. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology. 2015;44(4):199‐214.</Citation><ArticleIdList><ArticleId IdType="pubmed">25997994</ArticleId></ArticleIdList></Reference><Reference><Citation>Elser HC, Koch‐Henriksen N, Magyari M. Seasonal patterns of relapse and disability in danish MS patients: a population‐based cohort study. Multiple Sclerosis Related Disorders. 2021;49:102739.</Citation><ArticleIdList><ArticleId IdType="pubmed">33450501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel F. Factors involved in relapse of multiple sclerosis. J Microscopy Ultrastruct. 2019;7(3):103‐108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753697</ArticleId><ArticleId IdType="pubmed">31548920</ArticleId></ArticleIdList></Reference><Reference><Citation>Buljevac D, Flach HZ, Hop WCJ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(5):952‐960.</Citation><ArticleIdList><ArticleId IdType="pubmed">11960885</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed R, Manda N, T Estepa A. MULTIPLE SCLEROSIS AFTER COVID‐19: A SIGN OF THINGS TO COME? Chest. 2022;162(4):A2255.</Citation></Reference><Reference><Citation>Barzegar M, Vaheb S, Mirmosayyeb O, Afshari‐Safavi A, Nehzat N, Shaygannejad V. Can coronavirus disease 2019 (COVID‐19) trigger exacerbation of multiple sclerosis? A retrospective study. Multiple Sclerosis Related Disord. 2021;52:102947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8036166</ArticleId><ArticleId IdType="pubmed">33979771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G, Rinaldi V, Buscarinu MC, et al. Multiple sclerosis and SARS‐CoV‐2: has the interplay started? Front Immunol. 2021;12:755333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503550</ArticleId><ArticleId IdType="pubmed">34646278</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Multiple sclerosis and neuromyelitis optica spectrum disorder: onset following acute COVID‐19 infection, a case series. Neurol Ther. 2023;12(1):319‐327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9672646</ArticleId><ArticleId IdType="pubmed">36399224</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmann A, Metze C, Zettl UK, Loebermann M. Side effects following vaccination in multiple sclerosis: a prospective, multi‐centre cohort study. Sci Rep. 2023;13(1):14480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10475060</ArticleId><ArticleId IdType="pubmed">37660223</ArticleId></ArticleIdList></Reference><Reference><Citation>
Society NMS
. Vaccination in Multiple Sclerosis: NMSS; 2023.  [Available from: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Vaccinations
</Citation></Reference><Reference><Citation>Maniscalco GT, Scavone C, Moreggia O, et al. Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine‐vigilance study. Expert Opin Drug Saf. 2022;21(7):979‐984.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189777</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabizadeh F, Ramezannezhad E, Kazemzadeh K, Khalili E, Ghaffary EM, Mirmosayyeb O. Multiple sclerosis relapse after COVID‐19 vaccination: a case report‐based systematic review. J Clin Neurosci. 2022;104:118‐125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388441</ArticleId><ArticleId IdType="pubmed">36029752</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Dolev M, Menascu S, et al. COVID‐19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Multiple Sclerosis J. 2021;27(6):864‐870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114441</ArticleId><ArticleId IdType="pubmed">33856242</ArticleId></ArticleIdList></Reference><Reference><Citation>Aladdin YS, Alqarni DA, Alamoudi SW, et al. The safety profile of common COVID‐19 vaccines in patients with multiple sclerosis. Cureus. 2024;16(2):e54852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10964219</ArticleId><ArticleId IdType="pubmed">38533153</ArticleId></ArticleIdList></Reference><Reference><Citation>Czarnowska A, Tarasiuk J, Zajkowska O, et al. Safety of vaccines against SARS‐CoV‐2 among polish patients with multiple sclerosis treated with disease‐modifying therapies. Vaccines. 2022;10(5):763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147677</ArticleId><ArticleId IdType="pubmed">35632519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Seok HY. Evaluation of the safety profile of COVID‐19 vaccines in patients with MS, NMOSD, and MOGAD. Neurol Sci. 2023;44(6):1841‐1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9924883</ArticleId><ArticleId IdType="pubmed">36781562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nistri R, Barbuti E, Rinaldi V, et al. Case report: multiple sclerosis relapses after vaccination against SARS‐CoV2: A series of clinical cases. Front Neurol. 2021;12:765954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569136</ArticleId><ArticleId IdType="pubmed">34744992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>